How do you diagnose rheumatoid arthritis early?

Best Practice and Research: Clinical Rheumatology

Volumn 15, Issue 1, 2001, Pages 49-66

  Quinn, Mark A ^a   Green, Michael J ^a   Conaghan, Philip ^a   Emery, Paul ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Diagnosis; Early; Prognosis; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; GOLD; HLA DR4 ANTIGEN; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE;

ACUTE PHASE RESPONSE; CHRONICITY; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DOSE CALCULATION; DRUG EFFICACY; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; HUMAN; LABORATORY TEST; MEDICAL ASSESSMENT; MEDICAL SPECIALIST; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT REFERRAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHEUMATOID ARTHRITIS; STAGING; SYMPTOMATOLOGY; SYNOVITIS; TREATMENT OUTCOME;

EID: 0035040842     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1053/berh.2000.0125     Document Type: Article

References (69)

1. What is the natural history of rheumatoid arthritis?
2. The optimal management of early rheumatoid disease: The key to preventing disability
3. Biannual radiographic assessments of hands and feet in a three-year prospective follow-up of patients with early rheumatoid arthritis
4. High-resolution ultrasound defined subclinical synovitis - A predictor of outcome in early oligoarthritis?
5. The relationship between synovitis and bone changes in early untreated rheumatoid arthritis
6. What is early rheumatoid arthritis?: Definition and diagnosis
7. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
8. The value of the ACR 1987 criteria in very early rheumatoid arthritis
9. Diagnostic evaluation of classification criteria for rheumatoid arthritis and reactive arthritis in an early synovitis outpatient clinic
10. The performance of the 1987 ARA classification criteria for rheumatoid arthritis in a population based cohort of patients with early inflammatory arthritis
11. Persistence of mild early inflammatory arthritis: The importance of disease duration, rheumatoid factor and the shared epitope
12. Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome
13. Prognosis in inflammatory arthritis: The value of HLA genotyping and oncological analogy. The Dunlop Dotteridge Lecture
14. Outcome in oligoarthritis patients treated with IA corticosteroids to all clinically active joints
15. Factors predicting outcome of rheumatoid arthritis: Results of a follow up study
16. Dw4 is associated with persistence but not induction of arthritis
17. The prognosis of rheumatoid arthritis and undifferentiated polyarthritis syndrome in the clinic: A study of 1141 patients
18. Differentiating persistent from self-limiting symmetrical synovitis in an early arthritis clinic
19. Inflammatory polyarthritis in the community is not a benign disease: Predicting functional disability one year after presentation
20. Clinical course and remission rate in patients with early rheumatoid arthritis: Relationship to outcome after 5 years
21. Remission in rheumatoid arthritis
22. Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system
23. Generalised bone loss in patients with early RA occurs early and relates to disease activity
24. The acute phase and function in early rheumatoid arthritis. CRP levels correlate with functional outcome
25. Influence of prognostic features on the final outcome in rheumatoid arthritis: A review of the literature
26. Classification of inflammatory arthritis by enthesitis
27. An anatomical explanation for good prognosis rheumatoid arthritis
28. Serum C-reactive protein does not predict rheumatoid arthritis
29. Combined elevation of IgM and IgA rheumatoid factors has very high diagnostic specificity for rheumatoid arthritis
30. The distribution of class-specific rheumatoid factors is similar in rheumatoid and pre-illness sera
31. A prospective study on the incidence of rheumatoid arthritis among people with persistent increase in rheumatoid factor
32. Routine measurement of IgM, IgG and IgA rheumatoid factors: High sensitivity, specificity and predictive value for rheumatoid arthritis
33. Epidemiological study of HLA and GM in rheumatoid arthritis and related symptoms in an open Dutch population
34. Quantifying the exact role of HLA-DRBI alleles in susceptibility to inflammatory arthritis
35. The influence of HLA-DRBI alleles and rheumatoid factor on disease outcome in an inception cohort of patients with early inflammatory arthritis
36. The influence of HLA-DRβI genes on disease severity in rheumatoid arthritis
37. Strong primary selection for the Dw4 subtype of DR4 accounts for HLA-DQW7 association with Felty's syndrome
38. HLA heterozygosity contributes to susceptibility to rheumatoid arthritis
39. Genetic epidemiology of rheumatoid arthritis
40. Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome
41. A 1-year follow-up study of dynamic magnetic resonance imaging in early rheumatoid arthritis reveals synovitis to be increased in shared-epitope positive patients and predictive of erosions at 1 year
42. HLA-DRBI typing in rheumatoid arthritis: Predicting response to specific treatments
43. HLA and self-limiting, unclassified rheumatism. A role for HLA-B35
44. HLA-Bw35 and prognosis in adult onset Still's disease
45. Heterogeneity of HLA associations in systemic onset juvenile rheumatoid arthritis
46. A comparison of high resolution sonography with MRI and conventional radiography for the detection of erosions in early rheumatoid arthritis
47. MCPJ assessment in early RA: A comparison between Xray, MRI, high-resolution ultrasound and clinical examination
48. Asymptomatic synovitis precedes clinically manifest arthritis
49. Reversal of bony damage in early rheumatoid arthritis patients treated with IA corticosteroids and methotrexate: An MRI and ultrasonographic study
50. What does MRI tell us about RA therapy? Clinical outcomes from a randomised MRI outcome study of early RA patients
51. Clinical improvement and radiological deterioration in rheumatoid arthritis: Evidence that the pathogenesis of synovial inflammation and articular damage may differ
52. Long term mortality outcome in patients with rheumatoid arthritis: Early presenters continue to do well
53. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies
54. Clinical and radiographic outcomes of rheumatoid arthritis patients not treated with disease modifying drugs
55. Placebo-controlled studies in rheumatoid arthritis: Ethical issues
56. Sulfasalazine in early rheumatoid arthritis. A 48 week double-blind, prospective, placebo-controlled study
57. Should disease modifying drugs be used in mild rheumatoid arthritis?
58. Auranofin improves outcome in early rheumatoid arthritis. Results from a 2 year double-blind, placebo controlled study
59. Patients with early arthritis benefit from early 2nd line therapy: 5 year follow-up of a prospective double blind placebo controlled study
60. Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: Results of a five year prospective study
61. The effectiveness of early treatment with 'second-line' anti-rheumatic drugs. A randomised controlled trial
62. Combination therapy in early rheumatoid arthritis: A randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components
63. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: A randomised, controlled, double-blind, 52 week clinical trial
64. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind placebo, randomised, multicentre trial
65. Treatment of active rheumatoid arthritis and leflunomide compared with placebo and methotrexate
66. Sulfasalazine in early RA
67. A randomised trial of hydroxychloroquine in early rheumatoid arthritis: The HERA study
68. Quantitative microfocal radiography detects changes in erosion area in patients with early rheumatoid arthritis treated with myocrisine